The key products and services being delivered under this federal contract IDV award are radiopharmaceutical diagnostic imaging agents, specifically PYLARIFY (piflufolastat F-18), provided by Progenics Pharmaceuticals Inc., a subsidiary of Lantheus Holdings, Inc. The Department of Veterans Affairs (VA) is the primary funding agency for this single-award Indefinite Delivery Contract, valued at $5,052,208 with a period of performance through January 31, 2030.
Task orders issued under this IDV include a $1,010,441.60 firm fixed price delivery order for PYLARIFY injections to support the Imaging Department at the Salisbury VA Medical Center in North Carolina over a base year and four one-year option periods. The contract was awarded on a sole-source basis under the authority of FAR 13.106-1(b) for the procurement of this specialized radiopharmaceutical product used in positron emission tomography (PET) imaging to detect and stage prostate cancer. The contract supports VA healthcare facilities within the Veterans Integrated Service Network 6 (VISN 6) and aligns with the agency's mission to provide advanced diagnostic imaging capabilities to veterans.
Generated 2/1/25, 10:26 AM